In this articleABTDXCMFollow your favorite stocksCREATE FREE ACCOUNTZoom In IconArrows pointing outwardsUser wearing Stelo CGM from Dexcom.Courtesy of DexcomDexcom on Monday announced its new over-the-counter continuous glucose monitor Stelo is officially available for purchase in the U.S.Glucose is a type of sugar people receive from food, and it's the body's main source of energy.

在这篇文章中，abtdxcmfollow你最喜欢的股票创建免费账户放大iconwarns指向外面，戴着Dexcom的Stelo CGM。DexcomDexcom周一宣布，其新的非处方连续血糖监测仪Stelo在美国正式上市。葡萄糖是人们从食物中获得的一种糖，是人体的主要能量来源。

Continuous glucose monitors, or CGMs, are small sensors that poke through the skin to measure glucose levels in real time. They are typically prescribed to patients with diabetes since they can help alert users, their loved ones and their doctors to emergencies.Stelo is primarily intended for patients with prediabetes or Type 2 diabetes who do not use insulin, though individuals without either condition can also purchase it.

连续血糖监测仪（CGM）是一种小型传感器，可以穿透皮肤实时测量血糖水平。它们通常用于糖尿病患者，因为它们可以帮助提醒用户，他们的亲人和医生紧急情况。Stelo主要用于不使用胰岛素的糖尿病前期或2型糖尿病患者，尽管没有这两种情况的人也可以购买。

Users can buy a one-month supply online for $99, or sign up for an ongoing subscription at $89 a month. Dexcom said patients also have the option to use their Flexible Spending Accounts and Health Savings Accounts to pay for Stelo, according to a statement.The company already offers continuous glucose monitors for Type 1 and Type 2 diabetes patients, but Stelo is Dexcom's first product that does not require a prescription.

用户可以在线以99美元的价格购买一个月的供应，或者以每月89美元的价格注册持续订阅。Dexcom表示，根据一份声明，患者还可以选择使用灵活的支出账户和健康储蓄账户支付Stelo。该公司已经为1型和2型糖尿病患者提供了连续血糖监测仪，但Stelo是Dexcom的第一款不需要处方的产品。

While most Type 1 patients can already get insurance coverage for the sensors, Stelo is now accessible to millions of Type 2 patients who have been unable to get prescriptions or coverage. It also marks the company's official foray into a new and potentially lucrative prediabetes market. Dexcom said there are more than 125 million Americans with prediabetes or Type 2 diabetes not using insulin, according to a statement.

虽然大多数1型患者已经可以获得传感器的保险，但数百万无法获得处方或保险的2型患者现在可以使用Stelo。这也标志着该公司正式进军一个新的潜在利润丰厚的糖尿病前期市场。Dexcom表示，根据一份声明，有超过1.25亿美国人患有糖尿病前期或2型糖尿病，不使用胰岛素。

The company designed Stelo to help teach this patient population how to keep their glucose levels within a healthy range.   'The idea .

该公司设计了Stelo来帮助教这些患者如何将血糖水平保持在健康范围内。“这个主意。